Clinical Study Report - Calidad de Información CFR
Clinical Study Report - Calidad de Información CFR
Clinical Study Report - Calidad de Información CFR
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
ITT subjects to whom the study drug had been administered make up the FAS. All the FAS<br />
subjects who had completed the trial without serious protocol violation became the PP set.<br />
The safety population consisted of the study participants to whom the study drug was<br />
administered even partially. The analysis was done according to the drugs actually received.<br />
Of 124 subjects including 31 Clotinab patients from the stage 1, 84 subjects received Clotinab,<br />
and 40 received ReoPro ® . The ITT set consisited of all 124 patients. The FAS consisted of 123,<br />
83 Clotinab patients and 40 ReoPro ® patients. The PP set consisted of 112 patients, 76 Clotinab<br />
patients and 36 ReoPro ® patients.<br />
The FAS population was the safety analysis set.<br />
Details are shown in Appendix 16.2.2.<br />
11.2. Demographic and other baseline characteristics<br />
11.2.1. Demographic characteristics<br />
The distribution of subjects by diseases based on the coronary arteriostenosis ACC/AHA criteria<br />
<strong>de</strong>fined by angiography is as follows: 67 patients had one type C lesion characteristic,; 40<br />
patients had two type B lesion characteristics; 26 patients were refractory to drug treatmentin<br />
resting phase and with recurrent angina pectoris, and showed ischemic ST change in<br />
electrocardiogram; and 22 post-infarction angina patients were within 7 days after myocardial<br />
infarction attack that is refractory to drug treatment, and showed ischemic ST change in<br />
electrocardiogram. There was no significant difference in the distribution of disease status<br />
between two drug groups (Tables 11.2.1.1-3).<br />
Demographic characteristics of study participants were summarized in Table 11.2.1:4. There<br />
were 98 male patients and 26 female patients. The mean age was 58.8±10.50, the mean<br />
height 165.2±7.82cm and 165.1±8.00cm, and the mean weight was 68.7±12.09kg. There was<br />
no significant difference in these variables between two treatment groups.<br />
Demographic characteristics for the FAS population and the PP population were summarized in<br />
Table 11.2.1:5 and Table 11.2.1.6. There was no significant difference between two different<br />
groups in the FAS population or in the PP population.<br />
The Clotinab group was recruited in two stages, first 31 patients without randomization and<br />
CSR_Clotinab_II 46<br />
Ver. 1.0_Eng